Ka Leung Francis Chan - Biography#

Professor Chan, former Dean of the Faculty of Medicine of The Chinese University of Hong Kong and currently the Choh-Ming Li Professor of Medicine and Therapeutics of CUHK, started his research career 25 years ago on the prevention of gastrointestinal (GI) bleeding with anti-thrombotic agents and analgesics, which is an important cause of hospitalization and death in our aging population worldwide. His groundbreaking research has generated over 860 full scientific articles in high impact international journals, yielding an h-index of 130. Over the years, he has been an invited speaker at >260 regional / national / international scientific meetings and conferences.

Being a world leading expert in GI bleeding, he is the only non-US member of the Joint Expert Panel of The American Gastroenterology Association-American Herat Association-American College of Cardiology Foundation-American College of Gastroenterology to formulate clinical practice guidelines on the use of anti-thrombotic therapy in patients at risk of GI bleeding. He was also appointed by Asia-Pacific professional organizations to develop guidelines on the use of anti-thrombotics and analgesics and a member of the Maastricht Consensus for the Management of Helicobacter pylori infection. His extensive clinical research experience has put him in key positions in the pharmaceutical industry (e.g. Chairman of Steering Committee and a member of Data Safety & Monitoring Committee of multi-national clinical trials sponsored by Pfizer Inc, AstraZeneca, Merck, etc.) and earned him numerous honours and awards, visiting professorships and fellowships (Please refer to the attached short CV).

As the Board Chairman and Chief Medical Officer of GenieBiome Limited, a biotechnology start-up company co-founded by Professor Chan, he has successfully transformed his research on gut microbiome into novel innovations for early disease detection, prevention, and treatment, including novel diagnostic tests for recurrent colorectal neoplasia, post-acute COVID-19 syndrome, autism spectrum disorder etc. With his innovative research on gut microbiota in colorectal cancer, he led more than 10 international experts to publish the first clinical practice guidelines on the use of novel non-invasive tests to enhance colorectal cancer screening uptake in the Asia Pacific region.